Comparison

GHK-Cu vs
“GLOW”

One is a defined copper–peptide complex. The other is a name for a blend that lists it alongside two other peptides.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GHK-Cu is a copper–peptide complex, while “GLOW” is a blend name for GHK-Cu, BPC-157 and TB-500 together. GHK-Cu has small randomized human studies of specific skin formulations. In searches dated 21 November 2026, 6AM Research found no published study or registered trial of all three together. Regulatory and sport status must be read by component.

Key takeaways

  • GHK-Cu names a defined complex; “GLOW” names a blend listing GHK-Cu, BPC-157 and TB-500.
  • The 2006 Miller randomized human trial of a GHK-Cu skin formulation had 13 completers; material sold online is not the formulation tested.
  • 6AM Research found no published study or registered trial testing GHK-Cu, BPC-157 and TB-500 together in PubMed and ClinicalTrials.gov on 21 November 2026.
  • The World Anti-Doping Agency lists BPC-157 and TB-500 as prohibited at all times under separate classes.

01GHK-Cu vs “GLOW” in one table

QuestionGHK-Cu“GLOW”
IdentityGlycine, histidine and lysine form the three-amino-acid peptide GHK, which is bound to copper in GHK-Cu.A blend name for GHK-Cu, BPC-157 and TB-500 in one vial.
Evidence tierT1 for the design of a randomized human trial of a specific skin formulation, not a grade for every formulation. Material sold online is not the formulation tested.No study tier for the blend itself. Evidence grades for individual components do not transfer.
Human dataMiller et al. (2006): 13 patients completed a randomized study after laser skin resurfacing. Among the measures was skin redness. Material sold online is not the formulation tested.6AM Research found no published human study or registered trial testing GHK-Cu, BPC-157 and TB-500 together in PubMed and ClinicalTrials.gov on 21 November 2026.
United StatesThe FDA nomination list places GHK-Cu in Category 1, under evaluation, for certain routes of administration only.For the additional components, the Department of Health and Human Services draft compounding policy names BPC-157 and TB-500 individually and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice says the draft “is not binding”.
United KingdomThe emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK registerThe same for BPC-157 and TB-500
AustraliaThe TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own.The October 2026 Poisons Standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D, clause 5. These are component entries.
SportGHK-Cu is not named on the World Anti-Doping Agency’s 2026 or 2027 Prohibited List. WADA says a peptide not specifically named “may still be prohibited and may be harmful to health”.The 2026 Prohibited List names BPC-157 under S0 and TB-500 under S2.3. Both are prohibited in and out of competition.

02What differs, and what stays the same?

If you searched “ghk cu vs glow vs klow”, start with what each name identifies. The same GHK-Cu name appears in both ingredient lists. Neither list is a measurement of what is in a particular vial.

GHK-Cu: a defined complex

GHK-Cu identifies the peptide GHK bound to copper. It does not name a blend.

“GLOW”: three listed components

The name refers here to GHK-Cu, BPC-157 and TB-500 together.

“KLOW”: a fourth listed component

The “KLOW” label adds KPV to that list. For how the fourth ingredient changes what a lab report should show, see the “KLOW” guide.

The shared ingredient tells you where the names overlap. It does not make the blends interchangeable with GHK-Cu or with each other. A study of a GHK-Cu formulation is evidence about the formulation studied, not about what happens when other peptides are added.

03What did the human trial measure?

In 2006, Miller and colleagues randomized patients after laser skin resurfacing to skin-care formulations with or without GHK-Cu. Thirteen patients completed the trial. Researchers assessed redness and skin appearance and collected patient questionnaires. This is T1 for study design under 6AM Research’s evidence grades. It was a small trial of specific formulations. Material sold online is not the formulation tested.

For the blend, 6AM Research searched PubMed for names and synonyms of GHK-Cu, BPC-157 and TB-500, including searches with and without quotation marks and a broader search that also included thymosin beta names. It checked ClinicalTrials.gov by component. On 21 November 2026, those searches found no published study in any species or registered trial testing GHK-Cu, BPC-157 and TB-500 together.

A paper that discusses all three ingredients is not necessarily a study that tested them together. Check what the researchers actually compared.

04How to read the legal and sport records

  1. 14 May 2026FDA nomination list

    The updated list places GHK-Cu in Category 1 for certain routes of administration only. Category 1 means the bulk substance is under evaluation.

  2. 1 October 2026Australian Poisons Standard

    The October instrument names BPC-157 and TB-500 in Schedule 4, the prescription-only schedule, and in Appendix D, clause 5.

  3. 30 October 2026US draft compounding policy notice

    The Federal Register describes a draft policy that “is not binding”. Its list names BPC-157 and TB-500 individually, and it applies only to products with a single active ingredient listed in its Appendix A.

United Kingdom. Regulation 46(1) of the Human Medicines Regulations 2012 prohibits selling or supplying, or offering to sell or supply, an unauthorized medicinal product. Regulation 2(1) defines a medicinal product by how it is presented or by its function, including pharmacological, immunological or metabolic action to restore, correct or modify a physiological function, or use for medical diagnosis.

Sport. The World Anti-Doping Agency’s 2026 list applies on the date of this comparison. Its explanatory notes for 2027 caution that a peptide can still be prohibited and harmful to health even if the list does not name it. See how to read the anti-doping categories.

05What we don’t know

  • How GHK-Cu compares with the three-component blend in a controlled study. 6AM Research found no such comparison in PubMed or ClinicalTrials.gov on 21 November 2026.
  • What is actually in a vial from its name alone. A name states a label claim; it does not identify a batch.
  • Which listed peptides are present from a single purity percentage. That figure cannot establish each identity.

On a certificate of analysis, look for a matching batch number, a separate identity result for each listed peptide, and a separate measurement for each. A report on GHK-Cu alone cannot show whether BPC-157 or TB-500 was present. See how to read a certificate of analysis for the difference between identity, amount and purity.

This is a plain-English summary of public records, dated 21 November 2026, not legal or medical advice.

RefSources

  1. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. Nomination list, updated 14 May 2026. www.fda.gov/media/94155/download
  2. US Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendix A. Draft policy, October 2026; read on the Internet Archive capture of 11 Nov 2026 (hhs.gov returned 403 to our tools). web.archive.org/web/20261111210456/https://www.hhs.gov/sites…
  3. US Department of Health and Human Services. Notice of availability of draft peptide compounding policy, FR Doc. 2026-22192. Federal Register notice, 30 October 2026. public-inspection.federalregister.gov/2026-22192.pdf
  4. United Kingdom. Human Medicines Regulations 2012, SI 2012/1916, regulations 2(1) and 46(1). Statutory instrument, as made. www.legislation.gov.uk/uksi/2012/1916/pdfs/uksi_20121916_en.…
  5. Australian Government. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, F2026L01327. Schedule 4 and Appendix D. www.legislation.gov.au/F2026L01327/asmade/2026-09-30/text/or…
  6. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  7. World Anti-Doping Agency. Prohibited List 2026, S0 and S2.3. International Standard, in force from 1 January 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  8. World Anti-Doping Agency. Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List. Explanatory notes, S0. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. [Randomized human study of skin-care formulations with and without a copper tripeptide complex.] Arch Facial Plast Surg. 2006;8(4):252–259. PMID 16847171; abstract read 21 Nov 2026; PubMed lists no correction. journals.sagepub.com/doi/10.1001/archfaci.8.4.252
  10. PubMed search (title and abstract), GHK-Cu names AND BPC-157 names AND TB-500 or thymosin beta names: 7 results, each a review, commentary or letter. ClinicalTrials.gov intervention searches (GHK-Cu 4 records, BPC-157 4, TB-500 1): no record gives two or more of the three. Database searches, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28GHK%5Btiab%5D+OR+GHK-Cu%5Bt…
  11. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide, prezatide, BPC-157 and TB-500: “No search results” for each (control search, somatropin, returned results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=GHK

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is GHK-Cu another name for “GLOW”?

No. GHK-Cu is a defined copper–peptide complex. “GLOW” names a blend listing GHK-Cu alongside BPC-157 and TB-500.

Has a study compared GHK-Cu with “GLOW”?

6AM Research found no published study or registered trial comparing GHK-Cu with the blend of GHK-Cu, BPC-157 and TB-500 in PubMed and ClinicalTrials.gov on 21 November 2026.

What changes on a label that says “KLOW” instead of “GLOW”?

The “KLOW” label adds KPV to the three names on the “GLOW” label. The label does not verify the contents of a particular vial.

Which listed components does WADA prohibit in sport?

The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 under S0 and TB-500 under S2.3, both prohibited in and out of competition. GHK-Cu is not named; WADA says a peptide not specifically named “may still be prohibited and may be harmful to health”.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page